RxDoctor Payments Data

Anne Dean

Psychiatric/Mental Health · Jackson, MINPI 1457926701

Payments from drug & device makers

$4,815in general payments, 2019–2025

Across 295 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$887
  • Alkermes, Inc.$569
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$503
  • E.r. Squibb & Sons, L.L.C.$353
  • Vanda Pharmaceuticals Inc.$338
  • plus $1K from 6 others

What the payments were for

  • Food & beverage$4,70898%
  • Education$1072%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,815 in reported general payments places this provider in the 85th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$19,913
Medicare patients
28
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine21$131,918
IngrezzaValbenazine Tosylate16$127,647
Austedo XrDeutetrabenazine13$89,306
VraylarCariprazine Hcl103$70,974
Invega SustennaPaliperidone Palmitate19$52,804
LybalviOlanzapine/Samidorphan Malate34$42,862
FanaptIloperidone19$38,837
TrintellixVortioxetine Hydrobromide58$20,538
Lurasidone Hcl76$18,311
VivitrolNaltrexone Microspheres11$17,713
RexultiBrexpiprazole12$16,214
Clozapine197$14,827
Chlorpromazine Hcl38$8,458
ZyprexaOlanzapine19$7,886
Depakote ErDivalproex Sodium18$5,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$887$221,22434 claims
Neurocrine Biosciences, Inc.Ingrezza$213$127,64716 claims
AbbVieVraylar$171$70,974103 claims
Alkermes, Inc.Lybalvi, Vivitrol$569$60,57545 claims
Johnson & JohnsonInvega Sustenna$224$52,80419 claims
Vanda Pharmaceuticals Inc.Fanapt$338$38,83719 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,134$16,21412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Jackson

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →